| 2025-11-10 |
详情>>
股本变动：
变动后总股本26536.60万股
|
| 2025-11-10 |
详情>>
业绩披露：
2025年三季报(累计)每股收益0.03美元,归母净利润689.90万美元,同比去年增长114.80%
|
| 2025-11-10 |
财报披露：
美东时间 2025-11-10 盘前发布财报
|
| 2025-08-07 |
详情>>
业绩披露：
2025年中报每股收益0.03美元,归母净利润635.90万美元,同比去年增长123.94%
|
| 2025-06-30 |
详情>>
内部人交易：
Ostrowski Erik股份减少41314.00股
|
| 2025-05-08 |
详情>>
业绩披露：
2025年一季报每股收益0.03美元,归母净利润611.20万美元,同比去年增长133.98%
|
| 2025-04-29 |
股东大会：
将于2025-06-10召开股东大会
会议内容 ▼▲
- 1.Elect two Class II directors, John P. Butler and Myles Wolf, M.D., M.M.Sc., to serve until the 2028 annual meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier death, resignation or removal;
2.Approve an amendment to the Akebia Therapeutics, Inc. 2023 Stock Incentive Plan to increase the number of shares of common stock available for issuance thereunder by 18,900,000 shares and to make certain other changes to the plan;
3.Hold an advisory vote on the compensation of Akebia’s named executive officers;
4.Ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025;
5.Transact such other business as may properly come before the Annual Meeting or at any and all adjournments or postponements thereof.
|
| 2025-03-13 |
详情>>
业绩披露：
2024年年报每股收益-0.33美元,归母净利润-6941万美元,同比去年增长-33.67%
|
| 2024-11-07 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.22美元,归母净利润-4660.6万美元,同比去年增长11.29%
|
| 2024-08-08 |
详情>>
业绩披露：
2024年中报每股收益-0.13美元,归母净利润-2656.7万美元,同比去年增长30.18%
|
| 2024-05-09 |
详情>>
业绩披露：
2024年一季报每股收益-0.09美元,归母净利润-1798.5万美元,同比去年增长33.08%
|
| 2024-04-25 |
股东大会：
将于2024-06-06召开股东大会
会议内容 ▼▲
- 1.Elect three Class I directors, Ronald E. Frieson, Steven C. Gilman, Ph.D. and Cynthia Smith, to serve until the 2027 annual meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier death, resignation or removal;
2.Approve an amendment to the Akebia Therapeutics, Inc. 2023 Stock Incentive Plan to increase the number of shares of common stock available for issuance thereunder by 9,800,000 shares;
3.Hold an advisory vote on the compensation of Akebia’s named executive officers;
4.Ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024;
5.Transact such other business as may properly come before the Annual Meeting or at any and all adjournments or postponements thereof.
|
| 2024-03-14 |
详情>>
业绩披露：
2023年年报每股收益-0.28美元,归母净利润-5192.5万美元,同比去年增长44.89%
|
| 2023-11-08 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.28美元,归母净利润-5253.9万美元,同比去年增长40.40%
|
| 2023-08-28 |
详情>>
业绩披露：
2023年中报每股收益-0.2美元,归母净利润-3805万美元,同比去年增长-11.72%
|
| 2023-04-28 |
股东大会：
将于2023-06-06召开股东大会
会议内容 ▼▲
- 1.Elect three Class III directors, Adrian Adams, Michael Rogers and LeAnne M. Zumwalt, to serve until the 2026 annual meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier death, resignation or removal;
2.Approve the Akebia Therapeutics, Inc. 2023 Stock Incentive Plan;
3.Hold an advisory vote on the compensation of Akebia’s named executive officers;
4.Ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023;
5.Transact such other business as may properly come before the Annual Meeting or at any and all adjournments or postponements thereof.
|
| 2023-03-01 |
股东大会：
将于2023-04-11召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to our Ninth Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split at a ratio of not less than 1-for-5 and not greater than 1-for-20, with the exact ratio to be set within that range at the discretion of our Board of Directors prior to the one-year anniversary of the date on which the reverse stock split is approved by the Company’s stockholders at the Special Meeting without further approval or authorization of our stockholders and with our Board of Directors able to elect to abandon such proposed amendment and not effect the reverse stock split authorized by stockholders, in its sole discretion, and, in connection therewith, to decrease the number of authorized shares of our common stock on a basis proportional to the reverse stock split ratio (the “Reverse Stock Split Proposal”);
2.To approve an amendment to our Ninth Amended and Restated Certificate of Incorporation, as amended, to set the number of authorized shares of our common stock at a number determined by calculating the product of 350,000,000 multiplied by two times (2x) the reverse stock split ratio, subject to approval by our stockholders of the Reverse Stock Split Proposal and our implementation of a reverse stock split described in the proxy statement (the “Authorized Shares Proposal”);
3.To approve a proposal to adjourn the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Reverse Stock Split Proposal (the “Adjournment Proposal”).
|
| 2022-04-28 |
股东大会：
将于2022-06-08召开股东大会
会议内容 ▼▲
- 1.Elect two Class II directors, John P. Butler and Myles Wolf, M.D., M.M.Sc., to serve until the 2025 annual meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier death, resignation or removal;
2.Hold an advisory vote on the compensation of Akebia’s named executive officers;
3.Ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022;
4.Transact such other business as may properly come before the Annual Meeting or at any and all adjournments or postponements thereof.
|
| 2022-03-31 |
复牌提示：
2022-03-30 12:12:00 停牌，复牌日期 2022-03-30 14:05:00
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-22 |
股东大会：
将于2021-06-02召开股东大会
会议内容 ▼▲
- 1.Elect two Class I directors, Steven C. Gilman, Ph.D. and Cynthia Smith, to serve until the 2024 annual meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier death, resignation or removal;
2.Hold an advisory vote on executive compensation;
3.Ratify the appointment of Ernst & Young LLP, or Ernst & Young, as our independent registered public accounting firm for the fiscal year ending December 31, 2021;
4.Transact such other business as may properly come before the Annual Meeting or at any and all adjournments or postponements thereof.
|
| 2020-04-23 |
股东大会：
将于2020-06-05召开股东大会
会议内容 ▼▲
- 1.Elect three Class III directors, Adrian Adams, Maxine Gowen, Ph.D. and Michael Rogers, to serve until the 2023 annual meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier death, resignation or removal;
2.Approve an amendment to our Ninth Amended and Restated Certificate of Incorporation, or the Restated Certificate of Incorporation, to increase the number of authorized shares of our common stock, par value $0.00001 per share, or our Common Stock, from 175,000,000 to 350,000,000;
3.Hold an advisory vote on executive compensation;
4.Hold an advisory vote on the frequency of the advisory vote on executive compensation;
5.Ratify the appointment of Ernst & Young LLP, or Ernst & Young, as our independent registered public accounting firm for the fiscal year ending December 31, 2020;
6.Transact such other business as may properly come before the Annual Meeting or at any and all adjournments or postponements thereof.
|
| 2019-04-26 |
股东大会：
将于2019-06-06召开股东大会
会议内容 ▼▲
- 1.Elect three Class II directors, John P. Butler, Michael T. Heffernan, and Jodie P. Morrison, to serve until the 2022 annual meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier death, resignation or removal;
2.Ratify the appointment of Ernst & Young LLP, or Ernst & Young, as our independent registered public accounting firm for the fiscal year ending December 31, 2019;
3.Amend and restate our 2014 Employee Stock Purchase Plan to increase the number of shares of common stock, $0.00001 par value per share, or Common Stock, reserved for issuance under the plan to 5,763,545 and make certain other amendments;
4.Transact such other business as may properly come before the Annual Meeting or at any and all adjournments or postponements thereof.
|
| 2018-04-30 |
股东大会：
将于2018-06-14召开股东大会
会议内容 ▼▲
- 1.Elect three Class I directors, Michael D. Clayman, Duane Nash and Ronald C. Renaud, Jr., to serve until the 2021 annual meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier death, resignation or removal, and three Class III directors, John P. Butler, Muneer A. Satter and Michael S. Wyzga, to serve until the 2020 annual meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier death, resignation or removal;
2.Ratify the appointment of Ernst & Young LLP, or Ernst & Young, as our independent registered public accounting firm for the fiscal year ending December 31, 2018;
3.Transact such other business as may properly come before the Annual Meeting or at any and all adjournments or postponements thereof.
|
| 2017-05-01 |
股东大会：
将于2017-06-15召开股东大会
会议内容 ▼▲
- 1. Elect three Class III directors, John P. Butler, Muneer A. Satter and Michael S. Wyzga, to serve until the 2020 Annual Meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier resignation or removal;
2. Ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2017;
3. Transact such other business as may properly come before the meeting or at any and all adjournments or postponements thereof.
|
| 2016-04-29 |
股东大会：
将于2016-06-16召开股东大会
会议内容 ▼▲
- 1.Elect two directors, Maxine Gowen and Anupam Dalal, to serve as Class II directors until the 2019 Annual Meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier resignation or removal;
2.Ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2016;
3.Transact such other business as may properly come before the meeting or at any and all adjournments or postponements thereof.
|